Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910737 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Thomas Fischer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Hauptthemen laut MEDLINE: Neuroblastoma, Iodine Radioisotopes. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Preliminary studies on a radioactive antibody against the neural cell adhesion molecule (NCAM) demonstrated a significant accumulation of [131I]I-ERIC1 in neuroblastoma tumor cells in mice. This study aims to validate the therapeutic efficacy and potential adverse effects of these radioactive immunoconjugates (RICs) in neuroblastoma-bearing mice. To determine the highest tolerated dose, healthy SCID mice received 1 to 22 MBq of [131I]I-ERIC1, with the survival time measured. Tumor response was evaluated by administering 0.8 to 22 MBq of [131I]I-ERIC1 to neuroblastoma-bearing mice and assessing tumor size and systemic toxicity through body weight, blood counts, and survival. It was observed that doses up to approximately 3 MBq per animal (150 MBq/kg) were well tolerated, whereas higher doses resulted in systemic toxicity and death. The neuroblastomas exhibited a dose-dependent response, with optimal therapeutic efficacy achieved at 1.8–2.5 MBq per animal (90–125 MBq/kg), significantly extending survival by a factor of five. The antibody ERIC1 is a promising vehicle for the transport of beta emitters into NCAM-positive tumor tissue. An optimal dosage of the [131I]I-ERIC1 antibody can be established with a balance of tumor-static effects and adverse effects, resulting in a marked extension of survival time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
- Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Pediatric Oncology and Hematology, Center for Integrated Oncology, University of Cologne, 50937 Cologne, Germany.
- Department of Pain Management, Helios Hospital, 47805 Krefeld, Germany.
- School of Mathematics and Science, Inorganic Chemistry, University Wuppertal, 42119 Wuppertal, Germany.
- Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Straße, 52428 Jülich, Germany.
ORCID-Profile: Thomas Fischer, Felix Dietlein, Beate Zimmermanns, Matthias Schmidt, Fabian Mohr, Markus Dietlein
Zitieren
APA
Fischer, T., Dietlein, F., Bongartz, D., Klehr, M., Zimmermanns, B., Schmidt, M., Mohr, A., Mohr, F., Sudbrock, F., Krapf, P., Drzezga, A., Dietlein, M., & Schomäcker, K. (2024). Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910737
Vancouver
Fischer T, Dietlein F, Bongartz D, Klehr M, Zimmermanns B, Schmidt M, et al. Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910737
BibTeX
@article{Fischer2024,
author = {Fischer, Thomas and Dietlein, Felix and Bongartz, Detlev and Klehr, Martin and Zimmermanns, Beate and Schmidt, Matthias and Mohr, Angela and Mohr, Fabian and Sudbrock, Ferdinand and Krapf, Philipp and Drzezga, Alexander and Dietlein, Markus and Schomäcker, Klaus},
title = {Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910737}
}
EUVIMED